SCHEMBL19260827

SCHEMBL19260827

Clc1cc2c(Cl)c3ccccc3nc2cc1OCCCN1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.57
ALDH1A1 P00352 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CYP2D6 P10635 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
DNMT1 P26358 1/20 0.47
EHMT2 Q96KQ7 1/20 0.47
LTA4H P09960 1/20 0.46
HRH3 Q9Y5N1 7/20 0.46
HTR2A P28223 2/20 0.46
HTR7 P34969 2/20 0.46
HTR6 P50406 2/20 0.46
KCNH2 Q12809 4/20 0.46
ADRA1A P35348 2/20 0.46
TLR9 Q9NR96 1/20 0.46
TLR7 Q9NYK1 1/20 0.46
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260628 0.89 ACP1 (0.55) ACP1ALDH1A1SMN1; SMN2CYP2D6CYP2C19
SCHEMBL19260717 0.88 ACP1 (0.54) ACP1ALDH1A1SMN1; SMN2L3MBTL1DNMT1
SCHEMBL19260666 0.88 TLR7 (0.59) ACP1DNMT1EHMT2TLR9TLR7
SCHEMBL19260555 0.88 ACP1 (0.54) ACP1ALDH1A1SMN1; SMN2L3MBTL1DNMT1
SCHEMBL19260694 0.87 SPIN1 (0.58) ACP1DNMT1EHMT2TLR9TLR7
SCHEMBL19260540 0.86 ACP1 (0.53) ACP1ALDH1A1SMN1; SMN2CYP2D6CYP2C19
SCHEMBL19260586 0.84 CACNA2D1 (0.58) ACP1ALDH1A1SMN1; SMN2CYP2D6CYP2C19
SCHEMBL19260720 0.84 HRH3 (0.54) ACP1ALDH1A1SMN1; SMN2HRH3KCNH2
Formic Acid SCHEMBL19260731 0.81 ACP1 (0.50) ACP1ALDH1A1SMN1; SMN2CYP2D6CYP2C19
SCHEMBL19272512 0.79 EGFR (0.58) ALDH1A1HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 EP disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US disclosed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 EP disclosed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 ACP1 3686/4885ALDH1A1 1471/4885SMN1; SMN2 189/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 ACP1 3686/4885ALDH1A1 1471/4885SMN1; SMN2 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.